Navigation Links
Taiho Pharmaceutical stellt Zulassungsantrag zur Herstellung und Vermarktung des neuartigen Antitumormittels TAS-102
Date:2/26/2013

misierte Doppelblind-Vergleichsstudie von TAS-102 und einem Placebo. Laut Planung werden insgesamt 800 Patienten aus Japan, Nordamerika, Europa und Australien an dieser globalen klinischen Phase-III-Studie teilnehmen. Die Patientenrekrutierung begann im Juni 2012. Die an der Studie teilnehmenden Patienten leiden an inoperablen, rezidivierenden kolorektalen Karzinomen im fortgeschrittenen Stadium und sind für herkömmliche Chemotherapie unempfänglich (Fluoropyrimidin, Irinotecan, Oxaliplatin, Bevacizumab sowie monoklonale EGFR-Antikörper im Falle von KRAS-Wildtyp-Tumoren). Im Zuge der Vergleichsstudie werden Patienten nach dem Zufallsprinzip TAS-102 oder ein Placebo erhalten, um so die Wirksamkeit und Sicherheit von TAS-102 näher zu untersuchen. Das Gesamtüberleben ist der primäre Endpunkt der Studie. Die wissenschaftlichen Leiter sind Dr. Atsushi Otsu , Leiter des klinischen Entwicklungszentrums am National Cancer Center Hospital East (Japan), Dr. Robert J. Mayer des Dana Farber Cancer Institute (USA) und Dr. Eric Van Cutsem vom Universitätskrankenhaus Gasthuisberg (Belgien).

Informationen zu Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical, eine Tochtergesellschaft der Otsuka Holdings Co., Ltd. (http://www.otsuka.com/en/), ist ein auf Forschung und Entwicklung ausgerichtetes, spezialisiertes Pharmaunternehmen, das sich in erster Linie auf die drei Gebiete Onkologie, Allergien und Immunologie sowie Urologie konzentriert. Die Unternehmensphilosophie spiegelt sich in folgendem Versprechen wider: „Wir streben nach einer Verbesserung der menschlichen Gesundheit und wollen zur Bereicherung der Gesellschaft beitragen." Insbesondere im Bereich Onkologie ist Taiho Pharmaceutical in Japan'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
2. Taiho Pharmaceutical présente une demande dhomologation pour la fabrication et la commercialisation du nouvel agent antitumoral TAS-102
3. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
4. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
5. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
6. Global Pharmaceutical Industry Trends: Procurement Budgets Stay the Same, Marketing Budgets to Experience Slight Decrease
7. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
8. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
9. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
10. UBM Launches PharmaEvolution.com, an Online Peer-to-Peer Network for Pharmaceutical Industry Professionals
11. Alexza Pharmaceuticals Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma ... it will report its third quarter 2014 financial results ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... to the event can be obtained as follows: ...
(Date:10/19/2014)... Große Pharmafirmen werden oft ... dabei ist, dass große Pharmafirmen nicht willens sind, ... Es war deshalb nicht einfach, diesen ... mehr, dass es uns gelungen ist! Wir haben ... - mit einem Vorbehalt - einige haben uns ...
(Date:10/17/2014)... , Oct. 17, 2014 With the ... Affairs function has come across several challenges in ... and managing globalization.  The ... is dedicated to providing benchmarking and best practices ... Consortium is a service composed of three stages: ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... Inc. (Nasdaq: AUXL ) today announced that ... 31st Annual Health Care Conference during March 7-9, 2011 ... Chief Financial Officer, is scheduled to present an overview ... a.m. ET on Wednesday, March 9, 2011.   ...
... 2, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced that, ... determination from the NASDAQ Listing Qualifications Panel (the "Panel") ... for an extension to remain listed on The NASDAQ ...
Cached Medicine Technology:Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 3Nile Therapeutics Receives Positive NASDAQ Panel Decision 2Nile Therapeutics Receives Positive NASDAQ Panel Decision 3
(Date:10/20/2014)... The Advocator Group, LLC is ... Foundation for Suicide Prevention’s (AFSP) Out of the Darkness ... organization that hosts hundreds of community walks throughout the ... used to help understand and prevent suicide through not ... well. , The Advocator Group shares this passion ...
(Date:10/20/2014)... 20, 2014 Zereana Jess-Huff, a 34-year-old mother, ... 2014 on a platform to think outside the bra. She ... her position to raise awareness about women’s other lady parts. ... cancer. You say the color pink and everybody knows what ... a fact that it has not been won when it ...
(Date:10/20/2014)... Myoderm announced today the ... their CentralSource service. Matthew will play ... drug sourcing, distribution, and management service for international ... of industry experience, in both business development and ... their international success to help clients manage their ...
(Date:10/20/2014)... 2014 Final Cut Pro X Plugin developers ... Citrus theme for FCPX filmmakers . , “Fun, cool, ... the Citrus theme” Says Christina Austin, CEO of Pixel Film ... professional.” , Citrus comes with all the tools needed for ... four transitions for added style, a title screen for an ...
(Date:10/20/2014)... Maryland, USA (PRWEB) October 20, 2014 ... to track interventions? Here comes a wonderful app Metassessor ... mobile app development company helped its client “Intervention ... more efficiently. The app is designed for iOS 4.3 ... iPod touch. This app is optimized for iPhone 5. ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... BETHESDA, Md. (May 1, 2009) − Medical science took ... that, at least temporarily, perform the function of vital ... machine and renal dialysis, require the blood to be ... known as extracorporeal circulation (EC) and have provided critical ...
... in the May 1 issue of the journal SLEEP ... more likely to suffer from significant sleep disturbances at 2 ... of the study are of particular importance, as sleep disturbances ... depression in childhood. , Results indicate that infants ...
... who are wounded in combat as the result of a ... develop an abnormality known as heterotopic ossification. In this condition, ... near a fracture or other bone injury. New research conducted ... helping to pave the way for a better understanding of ...
... President pro Tem Darrell Steinberg (D-Sacramento) today announced ... Autism (ASD) & Related Disorders which will build ... the three-year California Legislative Blue Ribbon ... by Steinberg and ended in November 2008. ...
... (NYSE: BKD ) announced today that it plans to ... on Wednesday, May 6, 2009. The Company has also scheduled ... 2009 at 10:00 AM ET. The conference call can be ... 634-9069 (from outside of the U.S.) ten minutes prior to the ...
... news updates, features live, daily call-in shows hosted by world-class ... Ten Swine Flu FAQs at www.sirius.com/doctorradio , NEW ... (Nasdaq: SIRI ) has begun regular live updates ... health and medical channel powered by NYU Langone Medical Center. ...
Cached Medicine News:Health News:Chemical can reproduce complications for some patients 2Health News:Chemical can reproduce complications for some patients 3Health News:Chemical can reproduce complications for some patients 4Health News:Chemical can reproduce complications for some patients 5Health News:Maternal depression is associated with significant sleep disturbance in infants 2Health News:Injured Marines at risk for abnormal bone growth 2Health News:Steinberg Announces Senate Select Committee on Autism and Related Disorders 2Health News:Brookdale Announces First Quarter 2009 Release and Earnings Call 2Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 2Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 3Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 4Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 5Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 6
The Nine West Eyewear collection is positioned to present today's styles with a sharp, edgy contemporary attitude tied into a clean design element....
Inquire...
Inquire...
Inquire...
Medicine Products: